DALBHARAT:NSEDalmia Bharat Ltd. Analysis
Data as of 2026-03-15 - not real-time
₹1,890.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Dalmia Bharat’s shares are trading at ₹1,890, well below the 20‑day (₹1,998), 50‑day (₹2,078) and 200‑day (₹2,152) moving averages, signaling a bearish technical backdrop. The 14‑day RSI of 34.6 places the stock in oversold territory, suggesting a potential short‑term bounce. A bearish MACD with a widening negative histogram reinforces the downtrend, while the price sits just above the identified support at ₹1,822. Volume has been picking up, indicating renewed trader interest despite the overall price weakness. The market’s “Greed” sentiment (Fear‑Greed Index 72.9) further supports a contrarian view for a rebound. The current price also implies an upside of roughly 27 % to the analyst median target of ₹2,455.
On the fundamentals side, revenue grew 10 % year‑on‑year to ₹146.5 bn and gross margins remain robust at 61 %, but operating cash flow and free cash flow are reported as zero, raising sustainability concerns. The balance sheet is heavily leveraged, with a debt‑to‑equity ratio of nearly 40 × and total debt of ₹70.8 bn dwarfing cash of ₹50.3 bn. Earnings multiples are elevated (PE ≈30, forward PE ≈26) relative to the sector, yet the dividend payout is modest (0.49 % yield, 14 % payout), questioning dividend durability. Analysts remain bullish, assigning a “Buy” consensus and a mean price target of ₹2,403, reflecting confidence in the company’s margin profile and growth outlook. Considering the high 30‑day volatility (≈26 %) and low beta (≈0.1), the stock is prone to sharp moves but remains insulated from broader market swings. Overall, the blend of undervalued pricing, strong margins and a cautious capital structure suggests a measured buying opportunity with medium‑term upside potential.
On the fundamentals side, revenue grew 10 % year‑on‑year to ₹146.5 bn and gross margins remain robust at 61 %, but operating cash flow and free cash flow are reported as zero, raising sustainability concerns. The balance sheet is heavily leveraged, with a debt‑to‑equity ratio of nearly 40 × and total debt of ₹70.8 bn dwarfing cash of ₹50.3 bn. Earnings multiples are elevated (PE ≈30, forward PE ≈26) relative to the sector, yet the dividend payout is modest (0.49 % yield, 14 % payout), questioning dividend durability. Analysts remain bullish, assigning a “Buy” consensus and a mean price target of ₹2,403, reflecting confidence in the company’s margin profile and growth outlook. Considering the high 30‑day volatility (≈26 %) and low beta (≈0.1), the stock is prone to sharp moves but remains insulated from broader market swings. Overall, the blend of undervalued pricing, strong margins and a cautious capital structure suggests a measured buying opportunity with medium‑term upside potential.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Oversold RSI indicating potential bounce
- Price below key moving averages suggests discount
- Increasing trading volume supports near‑term interest
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 10% revenue growth and strong gross margins
- Analyst price targets imply ~27% upside
- Improving earnings outlook with forward EPS growth
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High debt‑to‑equity ratio raises leverage risk
- Zero operating cash flow questions cash generation
- Cyclical building‑materials sector adds medium‑term uncertainty
Key Metrics & Analysis
Financial Health
Revenue Growth10.20%
Profit Margin8.10%
P/E Ratio29.9
Debt/Equity39.76
P/B Ratio2.0
Technical Analysis
TrendBearish
RSI34.6
Support₹1,822.00
Resistance₹2,163.30
MA 20₹1,998.30
MA 50₹2,077.46
MA 200₹2,151.60
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Target Price₹2,403.32
Upside/Downside27.16%
GradeUndervalued
TypeBlend
Dividend Yield0.49%
Risk Assessment
Beta0.10
Volatility25.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.